---
layout: post
title: "Clinical Drug Interaction Studies With Combined Oral Contraceptives; Guidance for Industry; Availability"
date: 2026-02-05 18:55:48 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-12370
original_published: 2023-06-09 00:00:00 +0000
significance: 8.00
---

# Clinical Drug Interaction Studies With Combined Oral Contraceptives; Guidance for Industry; Availability

**Published:** February 05, 2026 18:55 UTC
**Source:** Federal Register
**Original Published:** June 09, 2023 00:00 UTC
**Document Number:** 2023-12370

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled "Clinical Drug Interaction Studies With Combined Oral Contraceptives." This guidance is intended to help sponsors of investigational new drug applications and new drug applications evaluate the need for drug-drug interaction (DDI) studies with combined oral contraceptives (COCs), design such studies, and determine how to communicate DDI study results and risk mitigation strategies to address potential risks associated with increased or decreased exposure of COCs in labeling. The guidance finalizes the draft guidance "Clinical Drug Interaction Studies With Combined Oral Contraceptives" issued on November 23, 2020.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/06/09/2023-12370/clinical-drug-interaction-studies-with-combined-oral-contraceptives-guidance-for-industry)
- API: https://www.federalregister.gov/api/v1/documents/2023-12370

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
